Trial Profile
Phase I Safety Study of Stereotactic Radiosurgery With Concurrent and Adjuvant PD-1 Antibody Nivolumab in Subjects With Recurrent or Advanced Chordoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2023
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Chordoma
- Focus Adverse reactions
- 03 Nov 2023 Planned End Date changed from 1 Nov 2023 to 1 Nov 2024.
- 03 Nov 2023 Planned primary completion date changed from 1 Nov 2023 to 1 Nov 2024.
- 03 Oct 2022 Status changed from recruiting to active, no longer recruiting.